...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Phase II trial of proton beam accelerated partial breast irradiation in breast cancer
【24h】

Phase II trial of proton beam accelerated partial breast irradiation in breast cancer

机译：质子束加速乳腺癌局部照射的II期试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose Here, we report the results of our phase II, prospective study of proton beam accelerated partial breast irradiation (PB-APBI) in patients with breast cancer after breast conserving surgery (BCS). Materials and methods Thirty patients diagnosed with breast cancer were treated with PB-APBI using a single-field proton beam or two fields after BCS. The treatment dose was 30 cobalt gray equivalent (CGE) in six CGE fractions delivered once daily over five consecutive working days. Results All patients completed PB-APBI. The median follow-up time was 59 months (range: 43-70 months). Of the 30 patients, none had ipsilateral breast recurrence or regional or distant metastasis, and all were alive at the last follow-up. Physician-evaluated toxicities were mild to moderate, except in one patient who had severe wet desquamation at 2 months that was not observed beyond 6 months. Qualitative physician cosmetic assessments of good or excellent were noted in 83% and 80% of the patients at the end of PB-APBI and at 2 months, respectively, and decreased to 69% at 3 years. A good or excellent cosmetic outcome was noted in all patients treated with a two-field proton beam at any follow-up time point except for one. For all patients, the mean percentage breast retraction assessment (pBRA) value increased significantly during the follow-up period (p = 0.02); however, it did not increase in patients treated with two-field PB-APBI (p = 0.3). Conclusions PB-APBI consisting of 30 CGE in six CGE fractions once daily for five consecutive days can be delivered with excellent disease control and tolerable skin toxicity to properly selected patients with early-stage breast cancer. Multiple-field PB-APBI may achieve a high rate of good-to-excellent cosmetic outcomes. Additional clinical trials with larger patient groups are needed.
机译：背景和目的在这里，我们报告了在保乳术后（BCS）的乳腺癌患者中，质子束加速部分乳房照射（PB-APBI）的前期II期研究的结果。材料和方法30例被诊断为乳腺癌的患者在BCS后使用单视野质子束或两视野进行PB-APBI治疗。在连续五个工作日中每天一次的六个CGE馏分中，治疗剂量为30钴灰色当量（CGE）。结果所有患者均完成PB-APBI。中位随访时间为59个月（范围：43-70个月）。在30例患者中，无同侧乳房复发或区域性或远处转移，所有患者均在最后一次随访中存活。医师评估的毒性为轻度至中度，除非一名患者在2个月时出现严重的湿性脱屑，超过6个月未观察到。在PB-APBI结束时和2个月时，分别对83％和80％的患者进行了定性的医师美容评估为良好或优良，而在3年时降至69％。在任何随访时间点，除一个外，所有接受两场质子束治疗的患者均观察到良好或优异的美容效果。在随访期间，所有患者的平均乳房回缩评估百分比（pBRA）值均显着增加（p = 0.02）;然而，接受两场PB-APBI治疗的患者并没有增加（p = 0.3）。结论PB-APBI由30个CGE和六个CGE馏分组成，连续5天每天一次，可以为适当选择的早期乳腺癌患者提供出色的疾病控制和可耐受的皮肤毒性。多场PB-APBI可以达到很高的良好至出色的美容效果。需要针对更大患者群的其他临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号